BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse CD40
?
產(chǎn)品描述:
FGK4.5-CP133單克隆抗體是原始FGK4.5單克隆抗體的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始FGK4.5克隆號相同,但是恒定區(qū)序列已經(jīng)從大鼠IgG2a變?yōu)樾∈驣gG2a。FGK4.5-CP133抗體像原始大鼠IgG2a抗體一樣,不包含F(xiàn)c突變。
?
FGK4.5-CP133單克隆抗體能與小鼠CD40(也稱為Bp50)反應。CD40是一種48 kDa的I型跨膜糖蛋白,屬于腫瘤壞死因子受體(TNFR)超家族。CD40廣泛表達于抗原呈遞細胞(APCs),如樹突狀細胞、B細胞、巨噬細胞和單核細胞,以及非免疫內(nèi)皮細胞、基底上皮細胞和一系列腫瘤細胞上。CD40與其配體CD154結(jié)合后,作為共刺激分子激活B細胞、樹突狀細胞、單核細胞和其他APCs。CD40在B細胞活化、分化、增殖和免疫球蛋白同種型轉(zhuǎn)換以及樹突狀細胞成熟中起作用。激動性CD40單克隆抗體已被證明能激活APCs并促進抗腫瘤T細胞反應。FGK4.5單克隆抗體是一種激動性抗體,已被證明能激活表達CD40的APC。FGK4.5單克隆抗體也可用于體外和體內(nèi)抑制CD40/CD154相互作用。
產(chǎn)品詳情:
產(chǎn)品名稱 | RecombiMAb anti-mouse CD40 |
產(chǎn)品貨號 | CP133 |
產(chǎn)品規(guī)格 | 1/5/25/50/100mg |
反應種屬 | Mouse |
克隆號 | FGK4.5-CP133 |
同種型 | Mouse IgG2a(switched from rat IgG2a) |
免疫原 | Recombinant mouse CD40 fusion protein |
實驗應用 | in vivo?CD40 activation* in vitro?B cell stimulation/activation* *Reported for the original rat IgG2a FGK4.5 antibody |
產(chǎn)品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 μm filtration |
純化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦同型對照 | InVivoPlus mouse IgG2a isotype control, unknown specificity(貨號BP0085) |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer(貨號IP0070) |
?
?該產(chǎn)品自上市已被多篇SCI文獻引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻引用:
應用 | 文章 |
體內(nèi)CD40激活 (in vivo CD40 activation) | 1.?Bauche, D., et al. (2018). 'LAG3(+) Regulatory T Cells Restrain?Interleukin-23- Producing CX3CR1(+) Gut-Resident Macrophages?during Group 3 Innate Lymphoid? Cell-Driven Colitis' Immunity 49(2): 342-352 e345. 2.?Carmi, Y., et al. (2015). 'Allogeneic IgG combined with dendritic cell stimuli induce? antitumour T-cell immunity' Nature 521(7550): 99-104. 3.?Conde, P., et al. (2015). 'DC-SIGN(+) Macrophages Control the Induction of? Transplantation Tolerance' Immunity 42(6): 1143-1158. 4.?Bartkowiak, T., et al. (2015). 'Unique potential of 4-1BB agonist antibody to promote? durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine' Proc? Natl Acad Sci U S A 112(38): E5290-5299. |
體外B細胞刺激/激活 (in vitro B cell stimulation/activation) | 1.?Xu, H., et al. (2015). 'Regulation of bifurcating B cell trajectories by mutual antagonism? between transcription factors IRF4 and IRF8' Nat Immunol . 2.?Muppidi, J. R., et al. (2014). 'Loss of signalling via Galpha13 in germinal centre? B-cell-derived lymphoma' Nature 516(7530): 254-258. ?? |
?
?
更多產(chǎn)品詳情請咨詢 BioXCell 中國授權(quán)代理——欣博盛生物
全國服務熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?
深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????
廣州:020-87615159????????? ?上海: 021-34613729
代理品牌網(wǎng)站: m.yuebanme.com?
自主品牌網(wǎng)站: www.neobioscience.net